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Lekarz Anna Szpotowicz jest absolwentką Wydziału Lekarskiego Uniwersytetu Medycznego w Białym-
stoku. Obecnie odbywa szkolenie specjalizacyjne z kardiologii na Oddziale Kardiologii Szpitala Powia-
towego w Ostrowcu Świętokrzyskim. W zakresie zainteresowań medycznych zajmują ją w szczególnoś-
ci terapia przeciwkrzepliwa, zaburzenia rytmu serca i leczenie choroby wieńcowej. W wolnym czasie 
lubi czytać książki i podróżować.
Abstract
Atrial fibrillation (AF) is the most common supraventricular arrhythmia. AF is characterised by disorganised atrial activa-
tion which leads to an impairment of atrial haemodynamic function and, in turn, to serious clinical consequences such 
as increased risks of heart failure, thromboembolism, and death. AF prevalence increases with age; in people aged 
< 50 years, the prevalence is 0.1%, whereas in those aged > 85 years it is 17.8%. Although men have a higher risk of 
AF compared to women, in women, AF more often is symptomatic and associated with more serious complications. 
Because female sex is a risk factor for thromboembolism, in 2012 the European Society of Cardiology recommended 
the use of the CHA2DS2-VASc score, which scores 1 point for being female, in assessing the thromboembolic risk in 
patients with AF.
Among hospitalised patients with AF (men and women), this study assessed the thromboembolic risk and evaluated 
anticoagulant use for stroke prevention.
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Statistical methods
Univariate and multivariate logistic regressions assessed 
prognostic properties of the analysed variables.
Statistical significance was interpreted as follows:
 — for p < 0.001, high statistical significance;
 — for p 0.001–0.005, statistical significance;
 — for p 0.05–0.1, statistical trend,
Med. Calc Ver. 12.4.0.0. software was used for all 
calculations.
Results
Among 6,820 patients discharged with AF in 2004–2012, 
4,099 patients with non-valvular AF were enrolled (Figu-
re 1), including 1,855 (42.3%) women and 2,244 (54.7%) 
men (p < 0.0001). The mean age was 70.6 years (± 10.9); 
in men the mean age was 68.2 (± 11.5); in women it was 
73.5 (± 9.4). There were 1,701 (41.5%) patients aged 
> 74 years (Table 1).
Paroxysmal AF was the most frequent AF type 
(1,875 patients, 45.7%; 925 women, 49.9%; 950 men, 
42.4%, p < 0.0001). Permanent AF was found in 1,767 pa-
tients (43.1%); 765 (41.2%) women, 1,002 men (44.6%); 
p = 0.0337. Thirty patients (0.7%) had newly diagnosed AF 
(19 women, 1.0%; 11 men, 0.5%; p = 0.0606). Persistent 
AF was found in 427 patients (10.4%); 146 women, 7.9%; 
281 men, 12.5%; p < 0.0001. Table 1 presents the frequ-
ency of comorbidities in the studied patients.
Women had a higher thromboembolic risk than men 
did. A high thromboembolic risk was found in 1,374 women 
(74.1%) and 1,385 men (61.7%) based on the CHADS2 sco-
re, and in 1,809 (97.5%) women and 1,799 (80.2%) men 
based on the CHA2DS2-VASc score (Table 2).
For thromboembolic prophylaxis, at discharge, 2,626 (64%) 
patients (1,167 women, 62.9%; 1,429 men, 63.6%) received 
an oral anticoagulant (OAC) alone or in combination with 
antiplatelet drugs; 821 (20%) patients (383 women, 20.6%; 
438 men, 19.5%) received acetylsalicylic acid (ASA) alone; 
87 (2.1%) patients (38 women, 1.6%; 49 men, 2.2%) re-
ceived low-molecular-weight heparins; 42 (1%) patients 
(21 women, 1.1%; 21 men, 0.9%) received clopidogrel alone; 
and 243 (59%) patients (126 women, 6.8%; 117 men, 5.2%) 
received no antiplatelet drugs or anticoagulants (Table 3).
Introduction
Atrial fibrillation (AF) is the most common supraventricular 
arrhythmia. AF is characterised by disorganised atrial acti-
vation which leads to an impairment of atrial haemodyna-
mic function and, in turn, to serious clinical consequences 
such as increased risks of heart failure, thromboembolism, 
and death [1–3]. AF prevalence increases with age; in 
people aged < 50 years, the prevalence is 0.1%, whereas 
in those aged > 85 years it is 17.8% [4]. Although men 
have a higher risk of AF compared to women, in women, 
AF more often is symptomatic and associated with more 
serious complications. Because female sex is a risk factor 
for thromboembolism, in 2012 the European Society of 
Cardiology recommended the use of the CHA2DS2-VASc 
score, which scores 1 point for being female, in assessing 
the thromboembolic risk in patients with AF [5].
Among hospitalised patients with AF (men and women), 
this study assessed the thromboembolic risk and evaluated 
anticoagulant use for stroke prevention.
Material and methods
Study population and inclusion criteria
This retrospective study analysed data of patients with AF 
who were hospitalised between 2004 and 2012 in a tertiary 
cardiology centre. The hospitalisations were due to elective 
procedures or emergency admissions.
The inclusion criterion was AF diagnosed during ho-
spitalisation.
The exclusion criteria were: valvular AF, in-hospital 
death, and incomplete data. In cases of multiple hospita-
lisations, data from the most recent hospitalisation was 
analysed.
Because the analysed data was acquired in 2004– 
–2012, the CHADS2 scores were used for thromboem-
bolic risk assessment. The CHADS2 scores assessed the 
following factors: stroke, transient ischaemic episode or 
peripheral embolism, age ≥ 75 years, hypertension, dia-
betes, and heart failure. The CHA2DS2-VASc scores were 
calculated retrospectively. In addition to the CHADS2 score, 
the CHA2DS2-VASc scores assessed the following factors: 
female sex, age 65–74 years, and vascular diseases.
Other variables
The HAS-BLED scale was used for bleeding risk assessment 
in patients with AF. The scale assessed the following fac-
tors: hypertension, abnormal liver or kidney function, prior 
stroke, prior bleeding or factors predisposing to bleeding, 
labile international normalised ratio (INR), age ≥ 65 years, 
use of antiplatelet drug(s) or non-steroidal anti-inflamma-
tory drugs, and alcohol abuse.
The glomerular filtration rate, calculated based on 
the Modification of Diet in Renal Disease Study formula, 
indicated kidney function.
Figure 1. Flow chart of patient enrolment in the current analysis
Patients hospitalised 
with atrial fibrillation
n = 6,820
Patients with atrial 
fibrillation included 
in the final analysis
n = 4,099
Patients with exclusion criteria
n = 2,721:
• valvular atrial fibrillation — 350
• in-hospital death — 320
• incomplete medical data — 387
• rehospitalisations — 1,664
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Among 2,626 patients who received an OAC alone 
or in combination with antiplatelet drugs, 180 (60.6%) 
had CHADS2 = 0.658 (63.2%) had CHADS2 = 1, and 
1,788 (64.8%) patients had CHADS2 ≥ 2 points. Among 
1,142 patients who received antiplatelet drug(s), 82 (27.6%) 
had CHADS2 = 0 points, 297 (28.5%) patients had CHADS2 = 
= 1 point, and 764 (27.7%) patients had CHADS2 ≥ 2 po-
ints. Among 248 patients discharged without any stroke 
prophylaxis, 28 (9.4%) patients had CHADS2 = 0 points, 
70 (6.7%) patients had CHADS2 = 1 point, and 145 (5.7%) 
patients had CHADS2 ≥ 2 points. Figure 2 presents stroke 
prophylaxis choices in women and men.
Table 1. Clinical characteristics of hospitalised women and men with atrial fibrillation
Clinical characteristic Total 
N = 4,099
Women 
N = 1,855
Men 
N = 2,244
p
Age:
• mean (SD), years 70.6 (± 10.9) 73.5 (± 9.4) 68.2 (± 11.5) < 0.0001
Age group:
• ≤ 50 years 3.4%; 139/4,099 1.1%; 20/1,855 5.4%; 119/2,244 < 0.0001
• 50–64 years 24%; 985/4,099 16.2%; 300/1,855 30.5%; 685/2,244 < 0.0001
• 65–74 years 31.1%; 1,274/4,099 30.1%; 571/1,855 31.3%; 703/2,244 NS
• ≥ 75 years 41.5%; 1,701/4,099 52%; 964/1,855 32.8%; 737/2,244 < 0.0001
Medical history:
• hypertension 74.8%; 3,067/4,099 81.4%; 1,511/1,855 69.3%; 1,556/2,244 0.0001
Coronary artery disease: 56.7%; 2,324/4,099 55.1%; 1,023/1,855 58%; 1,301/2,244 NS
• previous myocardial  
infarction
27.2%; 1,116/4,099 22.7%; 421/1,855 31%; 695/2,244 < 0.0001
• acute coronary syndrome 8.5%; 349/4,099 8.2%; 152/1,855 8.8%; 197/2,244 NS
• previous percutaneous  
coronary intervention
9.5%; 390/4,099 7.8%; 144/1,855 11%; 246/2,244 0.0005
Previous coronary artery by-
-pass grafting
3.7%; 152/4,099 1.9%; 36/1,855 5.2%; 116/2,244 < 0.0001
Heart failure 54.8%; 2,247/4,099 53.4%; 991/1,855 56%; 1,256/2,244 NS
Impaired renal function  
(GFR < 60 ml/min)
53.8%; 2,206/4,099 68.6%; 1,273/1,855 41.6%; 933/2,244 < 0.0001
Dyslipidaemia 19.8%; 811/4,099 20.8%; 386/1,855 18.9%; 425/2,244 NS
Diabetes mellitus type 2 21.8%; 893/4,099 24.2%; 448/1,855 19.8%; 445/2,244 0.0007
Thyroid disease 7.4%; 304/4,099 8.4%; 156/1,855 6.6%; 148/2,244 0.0286
Chronic obstructive  
pulmonary disease
4.2%; 173/4,099 3.7%; 68/1,855 4.7%; 105/2,244 NS
Malignancy 1.9%; 79/4099 0.6%; 12/1855 3.0%; 67/2244 < 0.0001
Previous thromboembolism:
• stroke 10.6%; 434/4,099 11.9%; 220/1,855 9.5%; 214/2,244 0.0129
• transient ischaemic attack 1.4%; 59/4,099 1.6%; 29/1,855 1.3%; 30/2,244 NS
• other thromboembolism 2%; 80/4,099 2.4%; 44/1,855 1.6%; 36/2,244 NS
SD — standard deviation; NS — not significant; GFR — glomerular filtration rate
Discussion
In this study, 55% of hospitalised patients with AF were 
male. Compared to women, the proportion of men was also 
higher in the ATRIUM registry [6], the Euro Heart Survey on 
Atrial Fibrillation [7], and the Registry of the German Com-
petence NETwork on Atrial Fibrillation [8]. In another study, 
of 613 patients discharged from a regional hospital, 51% 
were female [9]. In that study, the mean patient age was 
74.3 years, compared to 70.6 in our study; thus, the differ-
ence in sex distribution between our study and that study 
could be explained by the fact that AF prevalence in old age is 
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higher in women than in men, possibly because women have 
a longer life expectancy than men. In two studies performed 
in Turkey among patients with AF, women also outnumbered 
men (RMASES study, 55.9%; AFTER study, 60% [10, 11].
Table 2. Thromboembolic and bleeding risk of hospitalised women and men with atrial fibrillation
Variable Total 
N = 4,099
Women 
N = 1,855
Men 
N = 2,244
p
CHADS2
Mean ± SD 2.2 ± 0.7 2.4 ± 4.24 2.02 ± 2.12 < 0.0001
Median 2.5 3 1 < 0.0001
0 points 7.2%; 297/4,099 4.9%; 90/1,855 9.2%; 207/2,244 < 0.0001
1 point 25.4%; 1,042/4,099 21%; 390/1,855 29.1%; 652/2,244 < 0.0001
≥ 2 points 67.4%; 2,760/4,099 74.1%; 1,375/1,855 61.7%; 1,385/2,244 < 0.0001
CHA2DS2-VASc
Mean ± SD 3.7 ± 0.7 4.5 ± 4.95 2.98 ± 1.41 < 0.0001
Median 3.5 4.5 3.5 < 0.0001
0 points 3.1%; 127/4,099 – 56.6%; 127/2,244 –
1 point 8.9%; 364/4,099 2.5%; 46/1855 14.2%; 318/2,244 < 0.0001
≥ 2 points 88%; 3,608/4,099 97.5%; 1,809/1,855 80.2%; 1,799/2,244 < 0.0001
HAS-BLED
Mean ± SD 2.1 ± 0.7 2.4 ± 2.12  1.9 ± 1.02 < 0.0001
Median 3 0 2 < 0.0001
0–2 points 65.4%; 2,681/4,099 55.1%; 1,023/1,855 73.9%; 1,658/2,244 < 0.0001
≥ 3 points 34%; 1,418/4,099 44.9%; 832/1855 26.1%; 586/2,244 < 0.0001
CHA2DS2-VASc — cardiac failure or dysfunction, hypertension, age ≥ 75 [double], diabetes mellitus, stroke [double]-vascular disease, age 65–74, and sex category [female]; SD — standard deviation;  
CHADS2 — congestive heart failure, hypertension, age > 75 years, diabetes mellitus, and previous stroke or transient ischaemic attack [double]; HAS-BLED hypertension, abnormal renal/liver function, stroke, 
bleeding history, or predisposition, labile international normalised ratio, elderly, drugs/alcohol concomitantly
In this study, hypertension was the most common throm-
boembolic risk factor, and it affected women significantly 
more often than men (75% vs 69%). Thus, our results are 
in line with the GARFIELD study, in which women, too, had 
Table 3. Comparison of differences in antithrombotic prophylaxis between men and women
Treatment Total 
N = 4,099
Women 
N = 1,855
Men 
N = 2,244
p
Anticogulant treatment (OAC)
VKA (monotherapy) 57%; 2,336/4,099 58.3%; 1,081/1,855 55.9%; 1,255/2,244 NS
VKA + ASA + clopidogrel 3%; 125/4,099 2.7%; 50/1,855 3.3%; 75/2,244 NS
VKA + ASA 2.8%; 116/4,099 1.6%; 30/1,855 3.8%; 86/2,244 < 0.0001
VKA + clopidogrel 0.4%; 18/4,099 0.3%; 5/1,855 0.7%; 13/2,244 NS
Dabigatran 0.4%; 18/4,099 0.5%; 10/1,855 0.4%; 8/2,244 NS
Rivaroxaban 0.3%; 14/4,099 0.1%; 2/1,855 0.5%; 12/2,244 0.0238
Antiplatelet treatment
ASA (monotherapy) 20%; 821/4,099 20.6%; 383/1,855 19.5%; 438/2,244 NS
Clopidogrel (monotherapy) 1%; 42/4,099 1.1%; 21/1,855 0.9%; 21/2,244 NS
ASA + clopidogrel 6.8%; 279/4,099 5.9%; 109/1,855 7.6%; 170/2,244 0.0318
Other
Low molecular weight heparin 2.1%; 87/4,099 1.6%; 38/1,855 2.2%; 49/2,244 NS
Without prophylaxis 5.9%; 243/4,099 6.8%; 126/1,855 5.2%; 117/2,244 0.0308
OAC — oral anticoagulant; VKA — vitamin K antagonist; NS — not significant; ASA — acetylsalicylic acid
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hypertension more often than men (24% vs 20%) [12]. Also, 
compared to men, women more often had impaired kidney 
function (69% vs 42%) and type 2 diabetes (24% vs 20%). In 
this study, a significant proportion of patients with AF, both 
men and women, had ischaemic heart disease. Patients 
with AF in the Bialystok registry had a similar prevalence of 
ischaemic heart disease [13]. In this study, men more often 
than women had prior myocardial infarction, percutaneous 
coronary interventions, or coronary artery bypass grafting, 
which is in line with previous studies (GARFIELD [12], Euro 
Heart Survey on AF [7], GulfSAFE [14]). Female sex is an 
established cardiovascular risk factor. In this study, women 
more often than men had prior ischaemic stroke, but prior 
transient ischaemic attacks or peripheral embolism were 
equally common in men and women. A study from the 
GulfSAFE registry found that women more often than men 
had prior ischaemic attacks, but the rate of prior stroke did 
not differ between the sexes [16]. In the PREFER in AF regi-
stry, women, compared to men, had more thromboembolic 
complications [15]. Excluding women with lone AF aged < 
65 years, female sex is an independent thromboembolic risk 
factor [16, 17]. Thus, in 2012 the European Society of Car-
diology recommended the use of the CHA2DS2-VASc score, 
which scores 1 point for being female, for thromboembolic 
risk assessment in patients with AF [5].
Because this study analysed data of patients hospitali-
sed in 2004–2012, the CHADS2 score was used for thrombo-
embolic risk assessment; however, the CHA2DS2-VASc scores 
were calculated retrospectively. A high thromboembolic risk 
was found in 74% of women and 62% of men based on the 
CHADS2 score, and in 98% of women and 80% of men based 
on the CHA2DS2-VASc score. Because in the CHA2DS2-VASc 
score one point is given for being female, women had higher 
scores than men did. However, cardiovascular diseases, 
which, in our study, were more common in men than in wo-
men, are also included as a risk factor in the CHA2DS2VASc 
score. High CHADS2 and CHA2DS2-VASc scores were also 
more common in women than in men due to a higher fre-
quency of age ≥ 75 years, hypertension, diabetes, and prior 
stroke among women. A high thromboembolic risk was also 
more common in women than in men in earlier studies (Euro 
Heart Survey on AF [7], GARFIELD-AF [12, 18], Gulf SAFE 
[14], PREFER in AF [15]).
In our study, OACs alone were prescribed to men and 
women equally often, which is in line with studies from the 
GARFIELD-AF and Euro Heart Survey on AF registries that 
were performed in a similar period as this study [7, 12]. In 
the PREFER IN AF registry featuring 7,243 patients enrolled 
in 2012–2013, 95% of men and women received OACs 
[15]. In our study, men and women received ASA alone, 
or clopidogrel alone, at a similar frequency, but men were 
more likely to receive dual antiplatelet therapy due to 
a higher incidence of ischaemic heart disease. Interestingly, 
a higher proportion of women than men received no stroke 
prophylaxis (6.8% vs 5.2%). Among Swedish patients with 
AF, in 2007–2011, 17% received no stroke prophylaxis, 
both men and women, and in 2011–2015 that figure was 
15% in women and 17% in men [19]. Because the throm-
boembolic risk in this study was higher in women than in 
men, one could expect that women would be more likely to 
Figure 2. Antithrombotic prophylaxis in men and women according to score on CHADS2 (congestive heart failure, hypertension, age 
> 75 years, diabetes mellitus, and previous stroke or transient ischaemic attack [double]) scale; OAC — oral anticoagulant; AP — antiplate-
lets; LMWH — low-molecular-weight heparin
Women 
CHADS  = 0   
2
N = 90
AP OAC None of these
 
LMWH
4
10
24
62
Men 
CHADS  = 0   
2
N = 207
1.4
9.2
30
46.4
Women
 CHADS  = 1   
2
N = 390
1.5
9
28
61.5
Men
CHADS  = 1    
2
N = 652
2.6
5.5
28.8
64
Women 
CHADS  ≥ 2    
2
N = 1,375
2
6
27.8
64.2
Men 
CHADS  ≥ 2    
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N = 1,385
2,6
4,6
27,2
65,6
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receive anticoagulants; however, because the bleeding risk 
was also higher in women than in men, women were more 
likely than men to receive no anticoagulation.
Conclusions
1. Among hospitalised patients with AF, women were older 
than men. 2. High thromboembolic risk was found more 
frequently in women than in men, according to both the 
CHA2DS2-VASc and CHADS2 scores. 3. Among patients with 
AF, women were more likely than men to receive no stroke 
prophylaxis at discharge, whereas men were more likely 
than women to receive double antiplatelet therapy or an 
antiplatelet drug in combination with a vitamin K antago-
nist, possibly due to a higher incidence of ischaemic heart 
disease in men.
Streszczenie
Migotanie przedsionków (AF) jest najczęściej występującą arytmią, zarówno u mężczyzn, jak i u kobiet, polegającą na 
nieskoordynowanym pobudzeniu przedsionków, któremu może towarzyszyć szybka akcja komór. W Stanach Zjednoczo-
nych dotyka 1% dorosłych. Częstość występowania AF wzrasta istotnie z wiekiem i w populacji chorych powyżej 80. roku 
życia sięga aż 9%. Częściej na AF chorują mężczyźni, natomiast u kobiet arytmia ta częściej przebiega objawowo i jest 
obarczona groźniejszymi powikłaniami. Czynniki ryzyka AF z podobną częstością występowały u kobiet i mężczyzn, jed-
nak w ostatnich badaniach wykazano częstsze występowanie nadciśnienia tętniczego w grupie kobiet. U kobiet częściej 
występują powikłania zakrzepowo-zatorowe, dlatego płeć żeńska jest elementem ocenianym w skali CHA2DS2-VASc jako 
czynnik ryzyka zakrzepowo-zatorowego.
Celem pracy jest ocena czynników ryzyka zakrzepowo-zatorowego u hospitalizowanych kobiet i mężczyzn z AF.
Słowa kluczowe: udar mózgu, migotanie przedsionków, płeć
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